Q&A: Amgen's Alex Parker on Next-Gen Sequencing to Study Patient Response in Clinical Trials | GenomeWeb

AlexParkerPhoto2.jpgName: Alex Parker
Age: 43
Position: Principal scientist, Molecular Sciences group, Amgen, Cambridge, Mass., since 2006
Experience and Education:
Associate director (and other positions), Millennium Pharmaceuticals, 1997-2006

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.